Transcription of HPLC Column Classification
{{id}} {{{paragraph}}}
hplc Column ClassificationBrian Bidlingmeyer,*Agilent;Chung Chow Chan,{Eli Lilly and Company;Patrick Fastino,{FDA;Richard Henry,*ThermoHypersil Keystone;Philip Koerner,*Phenomenex;Anne T. Maule,{3M Pharmaceuticals;Margareth Marques,* Pharmacopeia;Uwe Neue,*Waters;Linda Ng*USP Pharmaceutical Analysis 2 Expert Committee;Horacio Pappa, ;Lane Sander,*NIST;Carmen Santasania,*Supelco;Lloyd Snyder,{LC Resources;Timothy Wozniak,*USPP harmaceutical Analysis 2 Expert CommitteeABSTRACTThisStimuliarticle represents the conclusions and recommendations of the USP Working Group on HPLCC olumns. The working group included the five largest manufacturers of hplc columns in the United States, along with theNational Institute of Standards and Technology (NIST) and USP. This work attempts to facilitate the selection of hplc columns by the analyst when performing a USP L nomenclature to designate high-performance liquidchromatography ( hplc ) Column type was introduced forthe first time in theFourth SupplementtoUSP XIXin1978.}}}}
Table 1. Characterization of C18 columns using NIST SRM 870 Column Number Hydrophobicity Capacity Factor (k’) Ethylbenzene Chelating Tailing Factor
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
COLUMN SELECTION Column Selection By USP, Column Selection, COLUMN SELECTION BY USP SPECIFICATIONS USP, United States Pharmacopoeia, Column, GC Column Selection and Optimizing Separations, GC Capillary Column Families, Reversed-Phase C18 Columns ODS, Reversed-Phase C18 Columns ( ODS, GC Section, Flow-Through Cell Apparatus USP Apparatus